1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6270FB503C3349522852575F30078EB08
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/report-summary-best-practices-for-internal-communications-regarding-brands-disease-state?OpenDocument
18
19OpenDocument
203.239.58.199
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services ╗ Business Communications Internal Communication Excellence

Report Summary: Best Practices for Internal Communications Regarding Brands & Disease State

ID: POP-229A


Features:

16 Info Graphics

20 Data Graphics

350 Metrics

50 Narratives

10 Best Practices


Pages: 14


Published: Pre-2016


Delivery Format: Online


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • VIEW TOC AND LIST OF EXHIBITS

For report summary, click
"Download FREE Excerpt".

Study Overview



When a promising new pharmaceutical product fails to meet expectations, poor brand communications may be a contributing cause. Successful brand leaders today must understand how and when to deliver complex key messages to all audiences -- including internal stakeholders -- to realize the best new product results.

This study is designed to help product teams avoid common pitfalls in internal communications that can hinder brand performance. The research also identifies and details 10 best practices for internal brand and disease state communications. Also covered are tactics,ástrategies and channels that are most effective for pre-launch disease state communication to employees across all job levels, corporate functions and therapeutic areas.
This report is intended for pharmaceutical, biotech and medical device managers and executives who supervise or interact with brand communications or new product development teams. The research will help pharma leaders to communicate the right internal message to the right employee segments at the right time to give the best possible support to product launch.


Key Topics

Ten best practices for internal disease state communication excellence
Effective communication channels & use of new communication technologies
Timing of communication activities by product development phase
Advantages & disadvantages of employee message segmentation
Tracking internal message effectiveness
Preventing sensitive-information leaks
Developing science-based communications
Using KOLs to influence employees
Special challenges for products treating socially sensitive conditions or diseases, first-in-class products, or new disease states or conditions
Needs creation marketing tactics
Success factors & guidelines

Key Metrics

Timing of first communication to key employee groups
Most important topics of communications before and after NDA filing
Relative effectiveness of internal communication channels for disease state education
Best metrics for evaluating internal message effectiveness for three product types:
--Established disease state products
--New disease state/ first-in-class product
--Product treating socially-sensitive disease
Expected usage levels of new communication technologies and channels
Companies customizing disease state communication for various management groups
Most important types of employee segmentation for three message types:
--Established disease state products
--New disease state/ first-in-class product
--Product treating socially-sensitive disease
Top challenges in internal communication about new products before launch

Methodology

The research involved a total of 32 research participants who referenced their combined experience with more than 100 product launches at 22 different companies. Best Practices, LLC, used a two-pronged approach for this benchmarking--an online benchmark survey and in-depth interviews with pharmaceutical brand and communications leaders. In all, 11 executives were interviewed. The survey focused on capturing quantitative data. Interviews harvested executive insights, process descriptions, best practices and pitfalls.

Industries Profiled:
Pharmaceutical; Biotech; Chemical; Health Care; Medical Device


Companies Profiled:
Abbott Laboratories; Sanofi-aventis; Actelion; Boehringer Ingelheim; Eli Lilly; Genentech; GlaxoSmithKline; Janssen; Merck Sharp & Dohme (MSD) China; Merck; Nektar Therapeutics; Novartis; Novo Nordisk; Pfizer; Roche; Schering-Plough; Takeda Pharmaceuticals; Vertex Pharmaceuticals; Watson Pharmaceuticals; Xanodyne Pharmaceuticals


Table of Contents

Research Overview 3
  • Key Findings 6
  • 10 Best Practices for Internal Disease State 12
Communications Excellence
  • Survey Response Data 64
  • Insights & Recommendations 75
  • Research Participant Demographics 80

List of Charts & Exhibits

Communications Excellence Involves 10 Key Practices
  • Summary of Internal Communication Challenges & Tactics
  • Communication Channel Effectiveness Ratings
  • Least Used Communication Channels
  • Anticipated Use of Social Media & Other New Channels
  • Communication Focus Before NDA
  • Communication Focus After NDA
  • Companies Providing Customized Education for Management
  • Use of Employee Segmentation in Messaging:
  • Top Ranked Segmentation Types for Products in Established Disease Areas
  • New/First-in-Class Products
  • Products Treating Socially-Sensititve Diseases or Conditions
  • Importance of Managing Message Alignment, Compliance, Science Education for Employees, Internal Message Effectiveness and Message Segmentation by Job Function
  • List of Participating Companies
  • Average Experience of Participants
  • Experience with Product Launch
  • Average Number of Product Launches per Participant
  • Participant Function/Department & Job Level
  • List of Products Participants Helped Launch